Breaking News Instant updates and real-time market news.

DEPO

Depomed

$24.10

0.27 (1.13%)

12:25
10/19/16
10/19
12:25
10/19/16
12:25

Depomed says no conference attendance 'certain' until confirmed

Depomed spokesperson Chris Keenan told The Fly in response to an inquiry that, as a policy, the company confirms attendance at conferences in a press release one week ahead of the presentation date. "Until this release, nothing should be considered as certain attendance," added Keenan. The request for comment follows rumors that circulated yesterday that claimed strength in Depomed shares was due to speculation the company canceled out of a planned conference appearance. According to The Fly's events team, Piper Jaffray is hosting its 28th Annual Healthcare Conference on November 29-30 and Depomed is scheduled to appear.

  • 29

    Nov

DEPO Depomed
$24.10

0.27 (1.13%)

10/04/16
MZHO
10/04/16
DOWNGRADE
MZHO
Neutral
Depomed downgraded to Neutral from Buy at Mizuho
Mizuho analyst Irina Koffler downgraded Depomed with a Buy due to valuation with a $27 price target on shares.
09/16/16
NORL
09/16/16
NO CHANGE
Target $30
NORL
Depomed price target raised to $30 to reflect takeover value at Northland
Northland raised Depomed's price target to $30 from $25 to reflect the reported $32 per share takeover value discounted by 6%. The firm's analyst said a company sale mandate could take place following issuance of a decision in Nucynta family patent litigation with a Federal District Court judge set to rule by end of September.
07/27/16
PIPR
07/27/16
DOWNGRADE
Target $18
PIPR
Neutral
Depomed downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst David Amsellem downgraded Depomed to Neutral citing "weak" prescription volume trends for secondary top-line drivers, particularly Gralise and Zipsor. Further, Nucynta trends continue to point to peak sales closer to $500M, below management's target of around $1B, the analyst contends. Amsellem lowered his price target for Depomed to $18 from $21.
07/07/16
07/07/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AT&T (T) downgraded to Neutral from Buy at Citi with analyst Michael Rollins citing valuation. 2. First Solar (FSLR) downgraded to Hold from Buy at Deutsche Bank with analyst Vishal Shah saying he sees downside risk to the company's 2017 earnings. 3. Depomed (DEPO) downgraded to Neutral from Buy at UBS with analyst Ami Fadia saying the company's sales guidance is at risk. 4. Red Hat (RHT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Keith Weiss saying mid-teens billings growth with flat to down margins limits upside to free-cash-flow projections and said valuation is fair to his $80 price target. 5. Bank of America (BAC) and Wells Fargo (WFC) downgraded to Market Perform from Outperform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.